Last $103.84 USD
Change Today +2.31 / 2.28%
Volume 105.8K
ALNY On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 10:29 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

alnylam pharmaceuticals inc (ALNY) Snapshot

Open
$102.51
Previous Close
$101.53
Day High
$104.12
Day Low
$101.79
52 Week High
12/8/14 - $111.49
52 Week Low
04/28/14 - $47.03
Market Cap
8.7B
Average Volume 10 Days
550.1K
EPS TTM
$-1.88
Shares Outstanding
83.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALNYLAM PHARMACEUTICALS INC (ALNY)

alnylam pharmaceuticals inc (ALNY) Related Businessweek News

View More BusinessWeek News

alnylam pharmaceuticals inc (ALNY) Details

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company’s clinical development programs include Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 that is in Phase I clinical trial for hemophilia and rare bleeding disorders; ALN-CC5, which is in Phase I/II clinical trial for the treatment of complement-mediated diseases; and ALN-PCSsc that is in Phase I clinical trial for hypercholesterolemia. Its product development programs also include ALN-AS1 for the treatment of hepatic porphyrias; ALN-AAT for the treatment of alpha-1 antitrypsin deficiency liver disease; ALN-GO1 for the treatment of primary hyperoxaluria type 1; ALN-TMP for the treatment of beta-thalassemia and iron-overload disorders; ALN-AC3 for the treatment of hypertriglyceridemia; ANGPTL3 for the treatment of hypertriglyceridemia and mixed hyperlipidemia; ALN-AGT for the treatment of hypertensive disorders of pregnancy, including preeclampsia; ALN-HBV for the treatment of Hepatitis B Virus; ALN-HDV for the treatment of HDV infection; and ALN-PDL for the treatment of chronic liver infections. The company has strategic alliances and collaboration agreements with Genzyme Corporation; The Medicines Company; Monsanto Company; F. Hoffmann-La Roche Ltd; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Tekmira Pharmaceuticals Corporation; The University of British Columbia; Acuitas Therapeutics Inc.; Takeda Pharmaceutical Company Limited; Protiva Biotherapeutics, Inc.; Biogen Idec Inc.; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Cubist Pharmaceuticals, Inc.; and Ascletis BioScience Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

256 Employees
Last Reported Date: 02/13/15
Founded in 2002

alnylam pharmaceuticals inc (ALNY) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $669.5K
President and Chief Operating Officer
Total Annual Compensation: $500.0K
Vice President of Finance and Treasurer
Total Annual Compensation: $252.1K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $450.0K
Compensation as of Fiscal Year 2013.

alnylam pharmaceuticals inc (ALNY) Key Developments

Alnylam Pharmaceuticals, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015

Alnylam Pharmaceuticals, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.

Alnylam Pharmaceuticals, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 09:30 AM

Alnylam Pharmaceuticals, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 09:30 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: John M. Maraganore, Chief Executive Officer and Executive Director.

Alnylam Pharmaceuticals, Inc. Announces Consolidated Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Alnylam Pharmaceuticals, Inc. announced consolidated unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net revenues from collaborators of $24,019,000 compared with $10,847,000 for the same period a year ago. Loss from operations was $45,712,000 compared with $29,592,000 for the same period a year ago. Loss before income taxes was $43,480,000 compared with $29,336,000 for the same period a year ago. Net loss was $21,389,000 or $0.28 per basic and diluted share compared with $32,357,000 or $0.51 per basic and diluted share for the same period a year ago. Non-GAAP net loss was $21,389,000 or $0.28 per basic and diluted share compared with $32,357,000 or $0.51 per basic and diluted share for the same period a year ago. For the year, the company reported net revenues from collaborators of $50,561,000 compared with $47,167,000 for the same period a year ago. Loss from operations was $404,980,000 compared with $92,942,000 for the same period a year ago. Loss before income taxes was $400,604,000 compared with $91,920,000 for the same period a year ago. Net loss was $360,395,000 or $4.85 per basic and diluted share compared with $89,225,000 or $1.45 per basic and diluted share for the same period a year ago. Non-GAAP net loss was $139,629,000 or $1.88 per basic and diluted share compared with $89,225,000 or $1.45 per basic and diluted share for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNY:US $103.78 USD +2.25

ALNY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$0.87 AUD +0.01
Enzon Pharmaceuticals Inc $1.02 USD -0.027
Galena Biopharma Inc $1.82 USD +0.015
Silence Therapeutics PLC 248.00 GBp 0.00
Tekmira Pharmaceuticals Corp C$22.59 CAD +0.04
View Industry Companies
 

Industry Analysis

ALNY

Industry Average

Valuation ALNY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 154.5x
Price/Book 8.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 154.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit www.alnylam.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.